1-2 of 2
Lucille A. Ferrante
Close
Sort by
Journal Articles

Pharmacological Characterization of JNJ-75276617, a Menin-KMT2A Inhibitor, As Targeted Treatment for KMT2A-Altered and NPM1-Mutant Acute Leukemia

Min Chul Kwon, Olivier Querolle, Xuedong Dai, Jan Willem Thuring, Tinne Verhulst, Ann Marien, Dries Goffin, Wei Cai, Vikki Keersmaekers, Filmon Eyassu, Karin Verstraeten, Sara El Ashkar, Shanna M Hogeling, Frank Jacob, Petra Vinken, Nicolas Darville, Vineet Pande, Daniel Krosky, Gregor Urbanietz, Bie Verbist, Lucille A. Ferrante, Christina Diane Drenberg, David Wilson, Ricardo M. Attar, Jan Jacob Schuringa, Nikki Daskalakis, Kathryn Packman, Christine Pietsch, Yusri Elsayed, Ulrike Philippar
Journal: Blood
Blood (2022) 140 (Supplement 1): 5928–5929.
https://doi.org/10.1182/blood-2022-168921
Published: 2022
Journal Articles

Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy

Jacob D. Soumerai, MD, Ai Ni, PhD, Mohamed Darif, PhD, Anil Londhe, PhD, Guan Xing, PhD, Yong Mun, PhD, Neil E. Kay, MD, Tait D. Shanafelt, MD, Kari G. Chaffee, MS, Richard R. Furman, MD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Jeff Sharman, MD, John F. Seymour, MBBS, PhD, Asher A. Chanan-Khan, MD, John C. Byrd, MD, Jeffrey A. Jones, MD MPH, Lucille A. Ferrante, MD, Lyndah K. Dreiling, MD, Mehrdad Mobasher, MD MPH, Thomas Stark, MD PhD, Vijay Reddy, MD PhD, Angela J. Howes, BSc, PhD, Danelle James, MD MAS, Pankaj Bhargava, MD, Andrew D. Zelenetz, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4394.
https://doi.org/10.1182/blood-2018-99-112989
Published: 2018